Nykode’s Phase 1/2 clinical trial will specifically address the emerging SARS-CoV-2 variants, with the DNA-based vaccines delivered intramuscularly with PharmaJet’s Stratis needle-free injection system.
The vaccines are designed to be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen, according to a news release. The initial focus for two of its candidates is as a booster vaccine for currently available vaccines, but Nykode may consider pursuing primary and therapeutic applications.
Golden, Colorado-based PharmaJet said both vaccines will be delivered exclusively needle-free. Earlier this year, another of PharmaJet’s partners — Scancell — chose PharmaJet’s delivery technology for its vaccine candidates.
“We are pleased that Nykode Therapeutics is moving into clinical trials with their DNA-based COVID-19 vaccines using our PharmaJet Needle-free Injection System,” PharmaJet President & CEO Chris Cappello said in the release. “As the fight continues against COVID-19, the integration of vaccine innovations with more efficacious delivery technologies, like needle-free jet injection, will be crucial for addressing the current and future pandemics.”
